Attached files

file filename
EX-99.1 - PRESS RELEASE - Processa Pharmaceuticals, Inc.hwux_ex991.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549


FORM 8-K


CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported)  July 17, 2017


Heatwurx, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware

333-184948

45-1539785

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)


530 S Lake Avenue #615, Pasadena, CA

91101

(Address of Principal Executive Offices)

(Zip Code)


Registrant’s telephone number, including area code:  (626) 364-5342



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ]  Written communications pursuant to Rule 425 under the Securities Act


[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act


[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act


[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act








Item 7.01  Regulation FD Disclosure.


On July 17, 2017, Heatwurx, Inc. (the “Company”) issued a press release entitled “Heatwurx Announces Letter of Intent with Promet Therapeutics, LLC Relating to a Reverse Merger” in which the Company disclosed that it has entered into a non-binding letter of intent to engage in a reverse merger with Promet Therapeutics, LLC. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.


In accordance with General Instruction B.2 of Form 8-K, the information in this report, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



Item 9.01  Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.

Description

99.1

Press Release dated July 17, 2017*


* Furnished to, not filed with, the SEC pursuant to Item 7.01 above.



















2




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

Heatwurx, Inc.

 

 

 

 

Date:  July 17, 2017

By  /s/ John P. McGrain

 

John P. McGrain, Interim Chief Executive Officer

and Interim Chief Financial Officer

































3